Tuesday is going to be a good day for Neurocrine Biosciences (NBIX)
and its shareholders. Strong data from the Phase IIb Kinect-2 study of
NBI-98854 ('854) in tardive dyskinesia surprised the Street in a big
way, and the shares are poised to jump as a potentially valuable drug
suddenly looks much more viable than just a few months ago.
When
it comes to the stock market and clinical trial data coming out of
biotechs, the reactions often remind me of a cat chasing a laser
pointer. Keep that in mind when contemplating the ultimate odds of
approval and the challenges in designing a Phase III study that will not
only cast the drug in the best light, but also satisfy the FDA's
demands. I'm still bullish on Neurocrine and still a shareholder myself,
but I'm not increasing my estimated fair value on the shares nearly as
much as the Street appears poised to in pre-market trading.
Click on this link to read more:
Kinect-2 Puts '854 Back Into Play For Neurocrine
No comments:
Post a Comment